Journal of Evidence-Based Dental Practice
Volume 8, Issue 4 , Pages 229-231 , December 2008

Oral Bisphosphonate Therapy may not Significantly Compromise Dental Implants Success

References 

  1. Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann Med. 1997;29:55–62
  2. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14(Suppl 2):53–65
  3. Greenspan SL, Harris ST, Bone H, Miller PD, Orwoll ES, Watts NB, et al. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis. Am Fam Physician. 2000;61:2731–2736
  4. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005;39:668–677
  5. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer. 2008;98(11):1736–1740
  6. Looker AC, Orwoll ES, Johnston CC, Lindsay RL, Wahner HW, Dunn WL, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761–1768
  7. Word Health Organization. Prevention and management of osteoporosis. Report of a WHO Scientific Group. Geneva, Switzerland: WHO Technical Report Series, No. 921, 2003.
  8. Burt BA. Epidemiology of dental diseases in the elderly. Clin Geriatr Med. 1992;8:447–459
  9. Budtz-Jørgensen E, Chung JP, Mojon P. Successful aging—the case for prosthetic therapy. J Public Health Dent. 2000;60:308–312
  10. Stanford CM. Dental implants. A role in geriatric dentistry for the general practice?. J Am Dent Assoc. 2007;138(Suppl):34S–40S
  11. Lewis S. Treatment planning: teeth versus implants. Int J Periodontics Restorative Dent. 1996;16:366–377
  12. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115–1117
  13. Ficarra G, Beninati F, Rubino I, Vannucchi A, Longo G, Tonelli P, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol. 2005;32:1123–1128
  14. Braun E, Iacono VJ. Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis. Int J Periodontics Restorative Dent. 2006;26:315–319
  15. American Dental Association Council on Scientific Affairs . Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144–1150
  16. Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis. Oral Maxillofac Surg Clin North Am. 2007;19:487–498
  17. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  18. Walter C, Grötz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2007;15:197–202
  19. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29:1548–1558
  20. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg. 2008;66:1022–1024
  21. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006;21:349–353
  22. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol. 2007;78:584–594
  23. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836
  24. Albrektsson T, Zarb G, Worthington P, Eriksson AR. The long-term efficacy of currently used dental implants: a review and proposed criteria of success. Int J Oral Maxillofac Implants. 1986;1:11–25
  25. Garnero P, Delmas PD. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone. 2003;32:20–26

PII: S1532-3382(08)00175-9

doi: 10.1016/j.jebdp.2008.09.007

Journal of Evidence-Based Dental Practice
Volume 8, Issue 4 , Pages 229-231 , December 2008

Article Tools